Glioma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in first line of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s glioma forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glioma over the forecast period?
- Of all cases diagnosed with glioma, how many are low grade, anaplastic, and glioblastoma or high grade?
- Of all people diagnosed with glioma, how many in each of the major mature pharmaceutical markets are eligible for drug treatment?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 16 glioma patient populations, including the following:
- Diagnosed glioma incident cases.
- Diagnosed astrocytic glioma incident cases.
- Diagnosed oligodendroglioma and oligoastrocytoma incident cases.
- Diagnosed oligodendroglioma incident cases.
- Diagnosed oligoastrocytoma incident cases.
- Diagnosed ependymal glioma incident cases.
- Diagnosed transformed glioblastoma glioma incident cases.
- Diagnosed astrocytic glioma prevalent cases.
- Diagnosed first-line glioblastoma glioma drug-treatable population.
Note: Coverage may vary by country.
Table of contents
- Glioma - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in / excluded from the analyses of glioma)
- Diagnosed glioma incident cases
- Glioma grade distribution
- Diagnosed transformed glioblastoma glioma cases
- Diagnosed astrocytic glioma prevalent cases
- Diagnosed first-line glioblastoma glioma drug-treatable population
- Risk / protective factors applied to disease forecast models
- Reference materials
